nach oben

Current Sexual Health Reports

Erschienen in:

25.10.2018 | Female Sexual Dysfunction and Disorders (T Lorenz and R Nappi, Section Editors)

Hormonal Contraception and Sexuality

verfasst von: Santiago Palacios, Mariella Lilue

Erschienen in: Current Sexual Health Reports | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to discuss controversies about hormonal contraception (HC) and sexuality, as well as to analyze sexual function according to the type of HC.

Recent Findings

HC has negative effects on sexual desire and lubrication, and may contribute to increased vestibular pain. Although there are several different types of HC, all alter the androgenic environment, which may have negative effects on sexual function. On the other hand, there may be reasons to support the use of HCs, and there can be improvement in sexuality associated with their use. For instance, there may be benefits for benign gynecological disorders such as endometriosis, menorrhagia, and dysmenorrhea. In addition, owing their contraceptive capacity, HC helps alleviate the fear of pregnancy, increasing the pleasure of the sexual experience. Another important aspect may be the relationship between hormonal contraceptives, body image and appearance, self-esteem, and sexuality.

Summary

There is sufficient evidence that HC may have both a positive and a negative impact on female sexuality. Additional research is needed on several key issues: searching for an HC without negative effects on sexuality, or with as little effect as possible; detecting women at risk of sexual dysfunction following initiation of HC; and finally, the possibility of adding androgens to HCs to minimize sexual side effects.

•• Higgins JA, Smith NK. The sexual acceptability of contraception: reviewing the literature and building a new concept. J Sex Res. 2016;53(4-5):417–56. https://doi.org/10.1080/00224499.2015.1134425 This study is a review of contraceptives and how they affect women’s well-being, in positive and negative ways.CrossRefPubMedPubMedCentral

Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999;181(5 Pt 1):1263–9.CrossRef

De Leo V, Musacchio MC, Cappelli V, Piomboni P, Morgante G. Hormonal contraceptives: pharmacology tailored to women's health. Hum Reprod Update. 2016;22(5):634–46.CrossRef

Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005;294:91–6.CrossRef

Davis SR, Bitzer J, Giraldi A, Palacios S, Parke S, Serrani M, et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J Sex Med. 2013;10(12):3069–79.CrossRef

Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update. 2006;12(2):169–78.CrossRef

Liening SH, Stanton SJ, Saini EK, Schultheiss OC. Salivary testosterone, cortisol, and progesterone: two-week stability, interhormone correlations, and effects of time of day, menstrual cycle, and oral contraceptive use on steroid hormone levels. Physiol Behav. 2010;99(1):8–16.CrossRef

Panzer C, Wise S, Fantini G, Kang D, Munarriz R, Guay A, et al. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: A retrospective study in women with sexual dysfunction. J Sex Med. 2006;3:104–13.CrossRef

Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, et al. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J Clin Pharmacol. 2007;47:497–509.CrossRef

10.

Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, et al. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception. 2007;75:430–7.CrossRef

11.

Coenen CM, Thomas CM, Bonn GF, Hollanders JM, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996;53:171–6.CrossRef

12.

Burrows LJ, Basha M, Goldstein AT. The effects of hormonal contraceptives on female sexuality: a review. J Sex Med. 2012;9(9):2213–23.CrossRef

13.

Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001;64:51–8.10.CrossRef

14.

Battaglia C, Battaglia B, Mancini F, Busacchi P, Paganotto MC, Morotti E, et al. Sexual behavior and oral contraception: A pilot study. J Sex Med. 2012;9:550–7.CrossRef

15.

• Čiaplinskienė L, Žilaitienė B, Verkauskienė R, Žalinkevičius R, Bumbulienė Ž, Vanagienė V. The effect of a drospirenone-containing combined oral contraceptive on female sexual function: a prospective randomised study. Eur J Contracept Reprod Health Care. 2016;1-7:16 This is a recent prospective study that showed the effects of EE + drospirenone on sexual function measured by FSFI.

16.

Graham CA, Ramos R, Bancroft J, Maglaya C, Farley TM. The effects of steroidal contraceptives on the well-being and sexuality of women: A double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception. 1995;52:363–9.CrossRef

17.

Cobey KD, Havlíček J, Klapilová K, Roberts SC. Hormonal contraceptive use during relationship formation and sexual desire during pregnancy. Arch Sex Behav. 2016;45(8):2117–22.CrossRef

18.

•• Guida M, Di Carlo C, Jacopo T, Gallo A, Cibarelli F, Martini E, et al. The sexuological impact of hormonal contraceptives based on their route of administration. Gynecol Endocrinol. 2017;33(3):218–22 This study discusses the different types of hormonal contraceptive methods and the impact on sexuality, comparing combined hormonal contraceptives, oral, vaginal, and progestin-only.CrossRef

19.

McCoy NL, Matyas JR. Oral contraceptives and sexuality in university women. Arch Sex Behav. 1996;25:73–90.CrossRef

20.

Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74:220–3.CrossRef

21.

Greenstein A, Ben-Aroya Z, Fass O, Militscher I, Roslik AND, Chen J, et al. Vulvar vestibulitis syndrome and estrogen dose of oral contraceptive pills. J Sex Med. 2007;4:1679–83.16.CrossRef

22.

Bouchard C, Brisson J, Fortier M, Morin C, Blanchette C. Use of oral contraceptive pills and vulvar vestibulitis: A case–control study. Am J Epidemiol. 2002;156:254–61.CrossRef

23.

Bohm-Starke N, Johannesson U, Hilliges M, Rylander E, Torebjork E. Decreased mechanical pain threshold in the vestibular mucosa of women using oral contraceptives: A contributing factor in vulvar vestibulitis? J Reprod Med. 2004;49:888–92.PubMed

24.

Goldstein A, Burrows L, Goldstein I. Can oral contraceptives cause vestibulodynia? J Sex Med. 2009;7:1585–7.CrossRef

25.

• Goldstein A, Belkin Z, Krapf J, Song W, Khera M, Jutrzonka S, et al. Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. J Sex Med. 2014;11:2764–71 This study investigates a possible cause of vestibulodynia in some women using hormonal contraceptives.CrossRef

26.

Caruso S, Cianci S, Malandrino C, Cicero C, Lo Presti L, Cianci A. Hyperandrogenic women treated with a continuous-regimen oral contraceptive. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):307–10.CrossRef

27.

Daniels K, Daugherty J, Jones J. Current contraceptive status among women aged 15-44: United States, 2011-2013. NCHS Data Brief. 2014;173:1–8.

28.

Shahnazi M, Bayatipayan S, Khalili AF, Kochaksaraei FR, Jafarabadi MA, Banoi KG, et al. Comparing the effects of the second-and third-generation oral contraceptives on sexual functioning. Iran J Nurs Midwifery Res. 2015;20(1):47–55.PubMedPubMedCentral

29.

Bishop JR, Ellingrod VL, Akroush M, Moline J. The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Hum Psychopharmacol. 2009;24(3):207–15.CrossRef

30.

Battaglia C, Morotti E, Persico N, Battaglia B, Busacchi P, Casadio P, et al. Clitoral vascularization and sexual behavior in young patients treated with drospirenone-ethinyl estradiol or contraceptive vaginal ring: a prospective, randomized, pilot study. J Sex Med. 2014;11(2):471–80.CrossRef

31.

Zimmerman AND, Foidart JM, Pintiaux A, Minon JM, Fauser BC, Cobey K, et al. Restring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects. Contraception. 2015;91(2):134–42.CrossRef

32.

Davis SR, Worsley R, Miller KK, Parish SJ. Santoro N androgens and female sexual function and dysfunction-findings from the fourth international consultation of sexual medicine. J Sex Med. 2016;13(2):168–78.CrossRef

33.

Tracy EE. Contraception: Menarche to menopause. Obstet Gynecol Clin North Am. 2017;44(2):143–58.CrossRef

34.

Galzote RM, Rafie S, Teal R, Mody SK. Transdermal delivery of combined hormonal contraception: a review of the current literature. Int J Womens Health. 2017;9:315–21.CrossRef

35.

Roumen FJ. Review of the combined contraceptive vaginal ring, NuvaRing. Ther Clin Risk Manag. 2008;4(2):441–51.CrossRef

36.

Roumen FJ, Mishell DR Jr. The contraceptive vaginal ring, NuvaRing®, a decade after its introduction. Eur J Contracept Reprod Health Care. 2012;17(6):415–27.CrossRef

37.

Caruso S, Cianci S, Malandrino C, Cicero C, Lo Presti L, Cianci A. Quality of sexual life of women using the contraceptive vaginal ring in extended cycles: preliminary report. Eur J Contracept Reprod Health Care. 2014;19(4):307–14.CrossRef

38.

Terrell LR, Tanner AE, Hensel DJ, Blythe MJ, Fortenberry JD. Acceptability of the vaginal contraceptive ring among adolescent women. J Pediatr Adolesc Gynecol. 2011;24(4):204–10.CrossRef

39.

Collaborative Study Group on the Desogestrel-Containing Progestogen-Only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 μg/day and levonorgestrel 30 μ/day. Eur J Contracep Reprod Health Care. 1998;14:169–78.

40.

Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;14:b2890.CrossRef

41.

Chakhtoura Z, Canonico M, Gompel A, Thalabard JC, Scarabin PY, Plu-Bureau G. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke. 2009;14:1059–1062El.CrossRef

42.

Schaffir J. Hormonal contraception and sexual desire: a critical review. J Sex Marital Ther. 2006;32(4):305–14.CrossRef

43.

Visconti F, Zullo F, Marra ML, De Masellis G, Caiazza M, Cibarelli F, et al. Guida M. A new long-term reversible contraception method: sexual and metabolic impact. Transl Med UniSa. 2012;4:86–9.PubMedPubMedCentral

44.

Duvan Cİ, Gözdemir E, Kaygusuz I, Kamalak Z, Turhan NÖ. Etonogestrel contraceptive implant (Implanon): analysis of patient compliance and adverse effects in the breastfeeding period. J Turk Ger Gynecol Assoc. 2010;11(3):141–4.CrossRef

45.

Di Carlo C, Sansone A, De Rosa N, Gargano V, Tommaselli GA, Nappi C, et al. Impact of an implantable steroid contraceptive (etonogestrel-releasing implant) on quality of life and sexual function: a preliminary study. Gynecol Endocrinol. 2014;30(1):53–6.CrossRef

46.

Wanyonyi SZ, Stones WR, Sequeira E. Health-related quality of life changes among users of depot medroxyprogesterone acetate for contraception. Contraception. 2011;84(5):e17–22.CrossRef

47.

Schaffir J, Fleming M, Waddell V. Patient perceptions regarding effect of gynecological surgery on sexuality. J Sex Med. 2010;7(2 Pt 1):826–31.CrossRef

48.

Grossman Barr N. Managing adverse effects of hormonal contraceptives. Am Fam Physician. 2010; 82(12).

49.

Schivone G, Dorflinger L, Halpern V. Injectable contraception: updates and innovation. Curr Opin Obstet Gynecol. 2016;28(6):504–9.CrossRef

50.

Gorgen H, Api M, Akça A, Cetin A. Use of the Levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. Arch Gynecol Obstet. 2009;279(6):835–40.CrossRef

51.

Bastianelli C, Farris M, Benagiano G. Use of the levonorgestrel-releasing intrauterine system, quality of life and sexuality. Experience in an Italian family planning center. Contraception. 2011;84(4):402–8.CrossRef

52.

Skrzypulec V, Drosdzol A. Evaluation of quality of life and sexual functioning of women using levonorgestrel-releasing intrauterine contraceptive system--Mirena. Coll Antropol. 2008;32(4):1059–68.PubMed

53.

Enzlin P, Weyers S, Janssens D, Poppe W, Eelen C, Pazmany E, et al. Sexual functioning in women using levonorgestrel-releasing intrauterine systems as compared to copper intrauterine devices. J Sex Med. 2012;9(4):1065–73.CrossRef

Titel: Hormonal Contraception and Sexuality
verfasst von: Santiago Palacios
Mariella Lilue
Publikationsdatum: 25.10.2018
Verlag: Springer US
Erschienen in: Current Sexual Health Reports / Ausgabe 4/2018
Print ISSN: 1548-3584
Elektronische ISSN: 1548-3592
DOI: https://doi.org/10.1007/s11930-018-0181-2

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Impact of Infertility on the Sexuality of Couples: an Overview

Sexual Desire in Women According to Reproductive Milestones

Penile Rehabilitation: the “Up”-date

Genito Pelvic Vaginal Laxity: Classification, Etiology, Symptomatology, and Treatment Considerations